Phase II trial of dasatinib for patients demonstrating acquired resistance to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib (E) or gefitinib (G).

被引：0
|
作者：
Johnson, Melissa L. [1 ]
Riely, Gregory J. [1 ]
Rizvi, Naiyer A. [1 ]
Azzoli, Christopher G. [1 ]
Kris, Mark G. [1 ]
Ginsberg, Michelle S. [1 ]
Pao, William [1 ,2 ]
Miller, Vincent A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Vanderbilt Univ, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S687 / S687
页数：1
相关论文
共 50 条
  • [1] Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
    Johnson, Melissa L.
    Riely, Greg J.
    Rizvi, Naiyer A.
    Azzoli, Christopher G.
    Kris, Mark G.
    Sima, Camelia S.
    Ginsberg, Michelle S.
    Pao, William
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1128 - 1131
  • [2] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS (TKIS) ERLOTINIB AND GEFITINIB IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC)
    Naskhletashvili, D. R.
    Gorbounova, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 435 - 435
  • [3] Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)
    Zhu, Lulin
    Yang, Xinxin
    Wu, Shanshan
    Dong, Rong
    Yan, Youyou
    Lin, Nengming
    Zhang, Bo
    Tan, Biqin
    DRUG METABOLISM REVIEWS, 2024, 56 (03) : 302 - 317
  • [4] Outcomes in Patients with Compound Epidermal Growth Factor Receptor (EGFR) Mutations After Treatment with Tyrosine Kinase Inhibitors (TKIs)
    Breslin, S.
    Thompson, J.
    Morrissette, J.
    Ciunci, C.
    Singh, A.
    Aggarwal, C.
    Cohen, R.
    Langer, C.
    Bauml, J.
    Marmarelis, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S839 - S839
  • [5] Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics
    van Zandwijk, N
    LUNG CANCER, 2006, 51 (01) : 137 - 138
  • [6] Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
    Xu, Yan
    Liu, Hongyu
    Chen, Jun
    Zhou, Qinghua
    CANCER BIOLOGY & THERAPY, 2010, 9 (08) : 572 - 582
  • [7] A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
    Han, Ji-Youn
    Lee, Ki Hyeong
    Kim, Sang-We
    Min, Young Joo
    Cho, Eunkyung
    Lee, Youngjoo
    Lee, Soo-Hyun
    Kim, Hyae Young
    Lee, Geon Kook
    Nam, Byung Ho
    Han, Hyesun
    Jung, Jina
    Lee, Jin Soo
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 10 - 19
  • [8] Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy
    Kanda, Shintaro
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Kubota, Kaoru
    Tamura, Tomohide
    Ohe, Yuichiro
    LUNG CANCER, 2015, 89 (03) : 287 - 293
  • [9] Rebiopsy of patients with "acquired resistance" to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Miller, Vincent A.
    Riely, Gregory J.
    Arcila, Maria E.
    Oxnard, Geoffrey
    Zakowski, Maureen F.
    Kris, Mark G.
    Pao, William
    Ladanyi, Marc
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S314 - S314
  • [10] Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
    Creelan, Ben C.
    Gray, Jhanelle E.
    Tanvetyanon, Tawee
    Chiappori, Alberto A.
    Yoshida, Takeshi
    Schell, Michael J.
    Antonia, Scott J.
    Haura, Eric B.
    BRITISH JOURNAL OF CANCER, 2019, 120 (08) : 791 - 796
12345